stock rating

The new revenue estimates come amid concerns about the effect of the Japanese earthquake, competition in the next-generation sequencing space, and government funding on the company's business.

The investment firm gave Fluidigm an "Outperform" rating and a valuation of between $17 and $18.

An Oppenheimer analyst noted the quality of Complete Genomics' data, a continued demand for sequencing service providers, and the progression of sequencing into clinical applications.

In a research note, analyst Quintin Lai noted the recent FDA approval of the protein biomarker-based test developer's Galectin-3 test, as well as partnerships forged with several IVD instrument manufacturers that could speed adoption of the test.

The eight firms for which Jefferies resumed coverage are Myriad Genetics, Cepheid, Gen-Probe, Complete Genomics, Exact Sciences, Genomic Health, Sequenom, and Nanosphere.

In addition to initiating coverage of Cepheid, Gen-Probe, Myriad Genetics, and Qiagen, the investment bank also began coverage of Alere and Hologic.

Despite the upgrade, an analyst expressed concern about the commercial value of the test, noting the cost involved.

Wedbush also placed a 12-month price target of $9 on Caliper's shares, saying that "new product traction in next-generation sequencing sample preparation as well as greater adoption of the company's products in molecular diagnostics can drive upside to consensus estimates."

The investment firm gave Illumina an "outperform" rating and an "aggressive growth" company profile.

In a research note, the investment house said that Caliper may be limited in its ability to exceed heightened expectations.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.